March 13, 2023
A California federal judge has thrown out a patent attorney's whistleblower suit against Allergan over dementia drug patents on remand from the Ninth Circuit, finding Monday that the public disclosure bar sinks the attorney's claims.
August 25, 2022
The Ninth Circuit has reversed a lower court decision that shut down pharmaceutical giant Allergan's bid to toss a patent attorney's whistleblower suit over dementia drug patents, determining Thursday that the attorney's claims tied to information from a patent proceeding trigger the public disclosure bar.
January 14, 2021
A patent attorney has urged a California federal judge to reject Allergan's bid to immediately appeal a ruling requiring the pharmaceutical giant to face a False Claims Act suit over patents for dementia medications, arguing the appeal would unnecessarily delay trial.
January 04, 2021
Allergan urged a California federal judge to allow it to immediately appeal his ruling requiring the pharmaceutical giant to face a False Claims Act suit over dementia drugs, arguing that decisions expected from separate, ongoing litigation could potentially resolve the suit brought by a patent attorney against the drugmaker.
December 11, 2020
A California federal judge rejected Allergan's bid to dodge a False Claims Act lawsuit Friday, finding the patent attorney behind the suit sufficiently alleged that the pharmaceutical company fraudulently obtained two dementia drug patents to allegedly monopolize pricing and out-compete generics.
June 09, 2020
California is supporting an attorney who filed a whistleblower lawsuit against Allergan Inc. alleging the pharmaceutical company fraudulently obtained patents to thwart generic competition and keep prices high, saying the attorney's claims could have a big impact on how much insurers pay for drugs.